$SKYE SEC Filings

Filed On	Filing
28 Oct 2026	PRER14A
26 Oct 2026	PREM14A
14 Oct 2026	SCHEDULE 13G
24 Sep 2026	Form 4: Schwab Andrew J., Director Sold 28,700 shares ($47.4K) · Sold 119,379 shares ($192K)
24 Sep 2026	Form 4: 5AM Partners VII, Llc, 10% owner and 7 others Sold 28,700 shares ($47.4K) · Sold 119,379 shares ($192K)
24 Sep 2026	SCHEDULE 13D/A
18 Sep 2026	Form 4: Schwab Andrew J., Director Sold 33,892 shares ($64.7K)
18 Sep 2026	Form 4: 5AM Partners VII, Llc, 10% owner and 7 others Sold 33,892 shares ($64.7K)
11 Sep 2026	DEFA14A
11 Sep 2026	8-K: Termination of a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Company provided writ...
24 Aug 2026	DEFA14A
24 Aug 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
20 Aug 2026	Form 4: Schwab Andrew J., Director Sold 300,000 shares ($114K) · Sold 68,140 shares ($23.8K) · Sold 7,700 shares ($2.46K)
20 Aug 2026	Form 4: 5AM Partners VII, Llc, 10% owner and 7 others Sold 300,000 shares ($114K) · Sold 68,140 shares ($23.8K) · Sold 7,700 shares ($2.46K)
20 Aug 2026	DEFA14A
20 Aug 2026	8-K/A: Material Modification to Rights of Security Holders The previously disclosed Certificate will become effective at 12:01 am New York time on Thursday, August 24, 2026, with the Company’s common stock to begin trading on The Nasdaq Stock Market LLC on a split-adjusted basis at market open o...
19 Aug 2026	DEFA14A
19 Aug 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
18 Aug 2026	SCHEDULE 13D/A
14 Aug 2026	DEFA14A

Comments